Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct 14:12:234-241.
doi: 10.33393/grhta.2025.3503. eCollection 2025 Jan-Dec.

Stima dei pazienti potenzialmente eleggibili alla terapia con icosapent etile in Italia mediante revisione dei dati di letteratura

[Article in Italian]
Pasquale Perrone Filardi  1 , Emanuela Arcangeli  2 , Pierluigi Carullo  3 , Carlotta Galeone  4   5 , Marcello Arca  6
Affiliations
Review

Stima dei pazienti potenzialmente eleggibili alla terapia con icosapent etile in Italia mediante revisione dei dati di letteratura

[Article in Italian]
Pasquale Perrone Filardi et al. Glob Reg Health Technol Assess. .

Abstract

Introduction:: The literature and international Guidelines agree in identifying LDL cholesterol (LDL-C) control as the primary goal for reducing cardiovascular (CV) risk, while hypertriglyceridemia management is a secondary objective. Nevertheless, experimental evidence indicates that elevated triglyceride levels represent a significant CV risk factor.

Epidemiological data about patients with hypertriglyceridemia and residual CV risk in Italy are limited. This study aims to estimate the prevalence of these patients that, despite treatment with high-intensity statins plus ezetimibe and LDL-C levels < 70 mg/dL, may be eligible for treatment with icosapent ethyl (IPE) in Italy.

Methods:: A literature review was performed to identify evidence on the reimbursed indication of IPE in Italy. Data from literature were used to estimate the number of patients eligible for IPE treatment by calculating a minimum, a maximum, and an average scenario.

Results:: A total of 94 articles were identified, which, after screening, were reduced to 7 articles included in the analysis. The analysis estimated a range of 2,500 to 78,590 total patients with residual hypertriglyceridemia potentially eligible for IPE treatment in Italy, with an average scenario of 22,427 patients.

The number of eligible patients will depend on the prescription and reimbursement criteria established by AIFA and the evolution of clinical practice concerning lipid-lowering therapies.

Conclusions:: The reported evidence may be useful for physicians and healthcare policymakers in managing residual CV risk in populations already treated for hypercholesterolemia, contributing to more effective prevention of CV events.

Keywords: Cardiovascular risk; Hypercholesterolemia; Hypertriglyceridemia; Icosapent ethyl; LDL cholesterol; Statins.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: EA and PC are AMARIN employees. PPF, CG, and MA have nothing to declare.

Figures

FIGURA 1 -
FIGURA 1 -
Flow chart di selezione degli articoli.
See this image and copyright information in PMC

References

    1. Vos T, Lim SS, Abbafati C et al. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi: 10.1016/S0140-6736(20)30925-9. https://doi.org/10.1016/S0140-6736(20)30925-9. https://pubmed.ncbi.nlm.nih.gov/33069326. - DOI - PMC - PubMed
    1. Vanuzzo D. La salute cardiovascolare degli italiani. Terzo Atlante Italiano delle Malattie Cardiovascolari - Edizione 2014. G Ital Cardiol (Rome). 2014;15(4):7–31. doi: 10.1714/1505.16549. https://doi.org/10.1714/1505.16549. - DOI
    1. Borén J, Chapman MJ, Krauss RM et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313–2330. doi: 10.1093/eurheartj/ehz962. https://doi.org/10.1093/eurheartj/ehz962. https://pubmed.ncbi.nlm.nih.gov/32052833. - DOI - PMC - PubMed
    1. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1):1–10. doi: 10.1007/s11883-011-0219-7. https://doi.org/10.1007/s11883-011-0219-7. https://pubmed.ncbi.nlm.nih.gov/22102062. - DOI - PMC - PubMed
    1. Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016;225:184–196. doi: 10.1016/j.ijcard.2016.09.075. https://doi.org/10.1016/j.ijcard.2016.09.075. https://pubmed.ncbi.nlm.nih.gov/27728862. - DOI - PubMed

LinkOut - more resources